Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540330 | 0.93 | OPRL1 (0.53) | OPRL1KCNH2OPRK1OPRM1CHEK1 | |
| SCHEMBL3540333 | 0.93 | OPRL1 (0.53) | OPRL1KCNH2OPRK1OPRM1CHEK1 | |
| SCHEMBL3543370 | 0.85 | OPRL1 (0.68) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3543309 | 0.77 | OPRL1 (1.00) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3539325 | 0.75 | OPRL1 (0.77) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3541425 | 0.75 | OPRL1 (0.79) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3549840 | 0.73 | OPRL1 (0.54) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3544004 | 0.73 | OPRL1 (0.77) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3540877 | 0.71 | OPRL1 (1.00) | OPRL1KCNH2OPRK1OPRM1 | |
| SCHEMBL3541721 | 0.70 | OPRL1 (0.79) | OPRL1KCNH2OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | OPRL1 1/4885KCNH2 766/4885OPRK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.